Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Albemarle Wins Anthera Contract

February 11, 2008 | A version of this story appeared in Volume 86, Issue 6

Albemarle has scored a contract to manufacture bulk quantities of varespladib, a cardiovascular disease drug from Anthera Pharmaceuticals that is in Phase III clinical trials. Scientists at Albemarle's South Haven, Mich., facility will optimize the production process and then manufacture the drug according to current Good Manufacturing Practices standards. Ontario-based Patheon will produce the finished tablet for the late-stage trials. Varespladib has shown promise in helping reduce inflammation and lower cholesterol levels in patients taking statin therapies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.